Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Solid Tumor × roniciclib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Fluorodeoxyglucose F18 7 Irinotecan 4 Fluorouracil 4 Bevacizumab 4 pembrolizumab 3 olaparib 3 Radiosurgery 3 Cyclophosphamide 3 Cisplatin 3 Capecitabine 3 vistusertib 2 toripalimab 2 tislelizumab 2 spartalizumab 2 fludarabine 2 atezolizumab 2 apatinib 2 Temozolomide 2 Radiotherapy 2 Proton Therapy 2 Paclitaxel 2 Leucovorin 2 Letrozole 2 Hydroxychloroquine 2 Everolimus 2 Drug Therapy 2 Docetaxel 2 tumor-cells apoptosis factor, human 1 trifluridine tipiracil drug combination 1 trametinib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02656849 2016-07-01

BAY 1000394 for MCL-1-, MYC-, and CCNE1-Amplified Tumors

Dana-Farber Cancer Institute

Phase 2 Withdrawn

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡